MT. KISCO, N.Y., June 4, 2013 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that the company plans to launch a new, proprietary dietary supplement in the U.S. alcohol consumption and hangover markets later this year.
Over 120 million American adults consume alcoholic beverages frequently. Approximately 1 in 6 adults binge drink, consuming an average of 4-8 alcoholic beverage four or more times a month, according to a 2010 report published by the Centers for Disease Control and Prevention (CDC). In January of 2013, the CDC released the findings of another study concluding that excessive alcohol consumption cost the United States taxpayers $223.5 billion in 2006. Approximately $161 billion, or 72% of these costs resulted from lost or decreased work productivity.
Karen Kingston, Chief Marketing Officer, stated, "The CDC statistics show that the majority of American adults drink and many drink excessively. Regardless of how much alcohol they consumed the night before, most Americans need to fulfill their daily professional and personal obligations the next morning. Based on the scientific evidence and market feedback that we have gathered so far, we believe our new proprietary, peri-/post- alcohol consumption (PAC) product will help improve the daily cognitive and physical functioning of people who enjoy drinking alcohol by priming their immune system."
Dr. Sven Rohmann, Global Chief Medical Officer, stated, "Most Americans are unaware that a hangover is not exclusively caused by dehydration and/or congeners, but also by the changing levels of cytokines in the body. For example, a clinical study of healthy males who consumed excessive amounts of clear, distilled alcohol combined with orange juice experienced statistically significant increases in certain cytokines, specifically interleukin-10, interleukin-12, and interferon gamma. High levels of such cytokines are associated with flu-like symptoms, including headache, fatigue, nausea, and vomiting.1
Separate studies have shown that acute alcohol exposure decreases the production of certain cerebral cytokines, including interleukin-1B, interleukin-6, and tumor necrosis factor-alpha. Scientific literature has shown that decreased levels of these cytokines result in 'sickness behavior', characterized by sleepiness, reduced activity, and the inability to concentrate."2
Mark McLaughlin, President and CEO, stated, "The launch of our proprietary PAC product will fill a large void - one of several market opportunities where we see potential in significantly monetizing our assets. As we position the Company for these opportunities, ImmuDyne is preparing for an exclusive event that will showcase our PAC product and provide us with valuable market feedback. Details of the event will be announced mid-June."
References: 1. Kim DJ, et al. Effects of Alcohol Hangover on Cytokine Production in Healthy Subjects. Alcohol. 2003. V31: 167-170. 2. Verster JC. The Alcohol Hangover – A Puzzling Phenomenon. Alcohol & Alcoholism. Jan 2008. V43, Num2: 124-126.
ImmuDyne is a health and wellness lifestyle company. ImmuDyne has a portfolio of unique patent-protected products with applications in the wellness lifestyle, skin care, anti-aging, fitness, and health markets. ImmuDyne has offices located in Mt. Kisco, NY, Carlsbad, CA, and Florence, Kentucky.
ImmuDyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
CONTACT: ImmuDyne, Inc. Mark McLaughlin +1-914-714-8901 MarkMcL@immudyne.comSource:ImmuDyne, Inc.